利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

8 条记录 (耗时 0.029 秒)

    Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein
    2.
    发明授权
    Method for identifying and using compounds that inactivate HIV-1 and other retroviruses by attacking highly conserved zinc fingers in the viral nucleocapsid protein 失效
    用于鉴定和使用通过攻击病毒核衣壳蛋白中高度保守的锌指而使HIV-1和其他逆转录病毒灭活的化合物的方法

    公开(公告)号：US06989263B1

    公开(公告)日：2006-01-24

    申请号：US09431607

    申请日：1999-11-01

    申请人： Louis E. Henderson ,  Larry O. Arthur ,  William G. Rice

    发明人： Louis E. Henderson ,  Larry O. Arthur ,  William G. Rice

    IPC分类号： C12H7/04 ,  C12H7/06 ,  C07C321/00 ,  C07D207/444

    CPC分类号： C12N7/00 ,  C12N2740/10063 ,  C12N2740/16063

    摘要： The present invention provides several classes of compounds which can be used to inactivate retroviruses, such as HIV-1, by attacking the CCHC zinc fingers of the viral nucleocapsid protein and ejecting the zinc therefrom. In addition, kits for identifying compounds that can react with CCHC zinc fingers of the nucleocapsid proteins of a large number of different retroviruses have also been developed. The kits of the present invention describe a set of specific tests and reagents that can be used to screen and identify compounds based on their ability to react with and disrupt retroviral zinc fingers in the viral NC proteins and, in turn, inactivate the retrovirus of interest.

    摘要翻译： 本发明提供几类可用于通过攻击病毒核衣壳蛋白的CCHC锌指并从其中排出锌而使逆转录病毒如HIV-1灭活的化合物。 此外，还开发了用于鉴定可与许多不同逆转录病毒的核衣壳蛋白的CCHC锌指反应的化合物的试剂盒。 本发明的试剂盒描述了一组特异性测试和试剂，其可用于根据其与病毒NC蛋白中的逆转录病毒锌指反应并破坏其逆转录病毒锌指的能力来筛选和鉴定化合物，从而使感兴趣的逆转录病毒失活 。

    HIV nucleocapsid protein capture assay and method of use
    3.
    发明授权
    HIV nucleocapsid protein capture assay and method of use 失效
    HIV核衣壳蛋白质捕获测定法和使用方法

    公开(公告)号：US5705331A

    公开(公告)日：1998-01-06

    申请号：US485833

    申请日：1995-06-07

    申请人： Larry O. Arthur ,  Louis E. Henderson

    发明人： Larry O. Arthur ,  Louis E. Henderson

    IPC分类号： C07K14/16 ,  C07K16/10 ,  G01N33/569 ,  C12Q1/70

    CPC分类号： C07K14/005 ,  C07K16/1054 ,  G01N33/56988 ,  C12N2740/16222 ,  G01N2800/52 ,  Y10S435/971 ,  Y10S435/974 ,  Y10S435/975

    摘要： An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable mount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human. Purified antibodies specifically reactive with an immunoreactive epitope specific to p7 or an immunoreactive fragment of p7 are also provided as well as an antigen capture method for detecting the presence of a lentivirus in a biological sample involving the nucleocapsid protein of the lentivirus.

    摘要翻译： 提供了用于检测生物样品中HIV的存在或浓度而不受抗原 - 抗体免疫复合物干扰的抗原捕获方法和抗原捕获测定诊断试剂盒。 将从动物获得的生物样品的裂解物与可检测的载体与核衣壳p7抗原或p7抗原的免疫反应性片段特异性反应的抗体接触一段时间并且在足以使裂解物中包含的p7抗原形成的条件下形成 p7抗体复合物。 确定该p7-抗体复合物的存在或浓度以检测或定量生物样品中HIV的存在。 该测定和方法的用途包括检测HIV感染母亲出生的婴儿中HIV感染的存在，监测HIV感染的进展，以及评估施用于动物（例如人）的抗HIV治疗的有效性 。 还提供与p7特异性的免疫反应性表位或p7的免疫反应性片段特异性反应的纯化抗体，以及用于检测涉及慢病毒的核衣壳蛋白的生物样品中慢病毒存在的抗原捕获方法。

    HIV Nucleocapsid protein capture assay and method of use
    4.
    发明授权
    HIV Nucleocapsid protein capture assay and method of use 失效
    HIV核衣壳蛋白质捕获测定法和使用方法

    公开(公告)号：US5462852A

    公开(公告)日：1995-10-31

    申请号：US967658

    申请日：1992-10-28

    申请人： Larry O. Arthur ,  Louis E. Henderson

    发明人： Larry O. Arthur ,  Louis E. Henderson

    IPC分类号： C07K14/16 ,  C07K16/10 ,  G01N33/569 ,  C12Q1/70

    CPC分类号： C07K14/005 ,  C07K16/1054 ,  G01N33/56988 ,  C12N2740/16222 ,  G01N2800/52 ,  Y10S435/971 ,  Y10S435/974 ,  Y10S435/975

    摘要： An antigen capture method, and an antigen capture assay diagnostic kit, for detecting the presence or concentration of HIV in a biological sample without interference from antigen-antibody immune complexes is provided. The lysate of a biological sample obtained from an animal is contacted with a detectable amount of an antibody specifically reactive with the nucleocapsid p7 antigen or an immunoreactive fragment of the p7 antigen for a time and under conditions sufficient for p7 antigen contained in the lysate to form a p7-antibody complex. The presence or concentration of this p7-antibody complex is determined to detect or quantitate the presence of HIV in the biological sample. Uses of this assay and method include detecting the presence of HIV infection in an infant born to an HIV-infected mother, monitoring the progression of HIV infection, and evaluating the effectiveness of an anti-HIV treatment administered to an animal, such as a human. Purified antibodies specifically reactive with an immunoreactive epitope specific to p7 or an immunoreactive fragment of p7 are also provided as well as an antigen capture method for detecting the presence of a lentivirus in a biological sample involving the nucleocapsid protein of the lentivirus.

    摘要翻译： 提供了用于检测生物样品中HIV的存在或浓度而不受抗原 - 抗体免疫复合物干扰的抗原捕获方法和抗原捕获测定诊断试剂盒。 将从动物获得的生物样品的裂解物与可检测量的与核衣壳p7抗原或p7抗原的免疫反应性片段特异性反应的抗体在足以使裂解物中包含的p7抗原形成的时间和条件下接触形成 p7抗体复合物。 确定该p7-抗体复合物的存在或浓度以检测或定量生物样品中HIV的存在。 该测定和方法的用途包括检测HIV感染母亲出生的婴儿中HIV感染的存在，监测HIV感染的进展，以及评估施用于动物（例如人）的抗HIV治疗的有效性 。 还提供与p7特异性的免疫反应性表位或p7的免疫反应性片段特异性反应的纯化抗体，以及用于检测涉及慢病毒的核衣壳蛋白的生物样品中慢病毒存在的抗原捕获方法。

    Design and construction of non-infectious human retroviral mutants deficient in genomic RNA
    5.
    发明授权
    Design and construction of non-infectious human retroviral mutants deficient in genomic RNA 失效
    设计和构建缺乏基因组RNA的非感染性人类逆转录病毒突变体

    公开(公告)号：US5674720A

    公开(公告)日：1997-10-07

    申请号：US176682

    申请日：1994-01-03

    申请人： Robert J. Gorelick ,  Larry O. Arthur ,  Alan Rein ,  Louis E. Henderson ,  Stephen Oroszlan

    发明人： Robert J. Gorelick ,  Larry O. Arthur ,  Alan Rein ,  Louis E. Henderson ,  Stephen Oroszlan

    IPC分类号： C07K14/15 ,  C07K14/16 ,  C12N13/00 ,  A61K39/21 ,  C07K1/00 ,  C12P21/06

    CPC分类号： C07K14/005 ,  C12N2740/16122

    摘要： The present invention defines a biological role for the following sequence of amino acids that is found in the nucleocapsid domain of the gag precursor polyproteins of all replication-competent retroviruses: -Cys-X-X-Cys-X-X-X-X-His-X-X-X-X-Cys- wherein X represents variable amino acids. The invariant residues constitute part of a vital protein structure, at least one of which are found in all retroviruses and which are involved in the selection and packaging of genomic viral RNA into infectious virus particles. Disruption of this structure leads to the formation of virus-like particles which appear to be structurally normal, but which do not contain the normal complement of viral RNA. Therefore, their infectivity is drastically reduced or completely eliminated. The infectivity of any retrovirus, including human retroviruses, and more particularly human immunodeficiency virus (HIV), can be drastically reduced or completely eliminated by generating mutants that lack some or all of the invariant residues required to form the structure. In addition, any means of disrupting the function of this array will in turn disrupt the viral life cycle. Thus, with the knowledge provided by this invention, chemotherapeutic reagents aimed toward this array may be devised.

    摘要翻译： 本发明限定了所有复制型逆转录病毒的gag前体多蛋白的核衣壳结构域中发现的以下氨基酸序列的生物学作用：-Cys-XX-Cys-XXXX-His-XXXX-Cys-，其中X 代表可变氨基酸。 不变残基构成重要蛋白质结构的一部分，其中至少一个存在于所有逆转录病毒中，并且参与将基因组病毒RNA选择和包装到感染性病毒颗粒中。 这种结构的破坏导致病毒样颗粒的形成，其似乎在结构上是正常的，但不包含病毒RNA的正常补体。 因此，它们的感染性大大降低或完全消除。 任何逆转录病毒（包括人类逆转录病毒，特别是人类免疫缺陷病毒（HIV））的感染性可以通过产生缺少形成结构所需的一些或全部不变残基的突变体而被大大降低或完全消除。 此外，破坏此阵列功能的任何方法将反过来破坏病毒生命周期。 因此，利用本发明提供的知识，可以设计针对这种阵列的化学试剂。